Get it on Google Play

Radiopharm gets approval to raise dose in cancer drug trial

October 1, 2025 8:00 AM EDT Send to a Friend
Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) received approval from its Data Safety and Monitoring Committee to increase the dosage of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login